Prime time for immune-checkpoint targeted therapy at ASCO 2015.

Abstract

Cancer immunotherapy has been one of the dominant topics in oral presentations and abstracts during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO). The renewed interest in immunotherapy is explained by the wide spectrum of activity, the durability of tumor responses and the rapid clinical development of immune-checkpoint targeted monoclonal antibodies. These new drugs are currently revolutionizing the field of oncology. Here we highlight what were to us the most important results announced during the annual meeting of ASCO held in Chicago, IL from May, 29th to June, 2nd 2015. In addition, we searched all the posters/published abstracts pertinent to the field of immunooncology from this year conference. Among more than 400 published abstracts on this topic, we have grouped and briefly summarized the most relevant ones.

• Authors: Aurélien Marabelle, Bertrand Routy, Judith Michels, Guido Kroemer, Laurence Zitvogel
• Journal: Oncoimmunology (Oncoimmunology) Vol. 5 Issue 3 Pg. e1068494 (Mar 2016) ISSN: 2162-4011 [Print] United States
• PMID: 27141332 (Publication Type: Review, Journal Article)